Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ocera Therapeutics Completes Tranzyme Merger | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ocera Therapeutics Completes Tranzyme Merger

Grais to serve as president and chief executive officer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ocera Therapeutics, Inc. and Tranzyme, Inc. have completed their merger. The combined company, called Ocera Therapeutics, Inc., will operate under the leadership of Linda S. Grais, MD, president and chief executive officer. The board of directors consists of representatives from both Ocera and Tranzyme.
 
Following the closing of the merger, certain Ocera investors, including Domain Associates, Thomas McNerney & Partners, Sofinnova Ventures, InterWest Partners, Greenspring Associates, Agechem, CDIB and Wasatch Advisors, invested approximately $20 million in the company through a private placement financing. The company now has approximately 11.3 million shares outstanding.
 
“The closing of this merger represents an important milestone as Ocera joins forces with Tranzyme to develop OCR-002, a differentiated product candidate for orphan liver diseases,” said Dr. Grais. “We look forward to advancing OCR-002, currently in Phase II development, to address a significant unmet need in the treatment of hepatic encephalopathy in patients with decompensated liver cirrhosis.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters